Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 404

1.

Is blood pressure measured correctly in dialysis centres? Physicians' and patients' views.

Pappaccogli M, Labriola L, Van der Niepen P, Pruijm M, Vogt L, Halimi JM, Ferro CJ, Halabi G, Phan O, Bullani R, Saudan P, Avdelidou A, Panou E, Papoulidou F, London G, Rossignol P, Sarafidis P, Persu A, Wuerzner G.

Nephrol Dial Transplant. 2019 Jul 13. pii: gfz125. doi: 10.1093/ndt/gfz125. [Epub ahead of print] No abstract available.

PMID:
31302688
2.

Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction.

Hall TS, von Lueder TG, Zannad F, Rossignol P, Duarte K, Chouihed T, Solomon SD, Dickstein K, Atar D, Agewall S, Girerd N; High-Risk Myocardial Infarction Database Initiative investigators.

Am Heart J. 2019 Jun 12;215:83-90. doi: 10.1016/j.ahj.2019.06.004. [Epub ahead of print]

PMID:
31291604
3.

Soluble ST2 promotes oxidative stress and inflammation in cardiac fibroblasts: An in vitro and in vivo study in aortic stenosis.

Matilla L, Ibarrola J, Arrieta V, Garcia-Peña A, Martinez-Martinez E, Sádaba R, Alvarez V, Navarro A, Fernández-Celis A, Gainza A, Santamaría E, Fernández-Irigoyen J, Bayes-Genis A, Rossignol P, López-Andrés N.

Clin Sci (Lond). 2019 Jul 8. pii: CS20190475. doi: 10.1042/CS20190475. [Epub ahead of print]

PMID:
31285364
4.

Chest X-ray quantification of admission lung congestion as a prognostic factor in patients admitted for worsening heart failure from the ICALOR cohort study.

Kobayashi M, Bercker M, Huttin O, Pierre S, Sadoul N, Bozec E, Chouihed T, Ferreira JP, Zannad F, Rossignol P, Girerd N.

Int J Cardiol. 2019 Jun 26. pii: S0167-5273(19)30635-7. doi: 10.1016/j.ijcard.2019.06.062. [Epub ahead of print]

PMID:
31281047
6.

Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial (MIRAD trial).

Johansen ML, Schou M, Rossignol P, Holm MR, Rasmussen J, Brandt N, Frandsen M, Chabanova E, Dela F, Faber J, Kistorp C.

Diabetes Obes Metab. 2019 Jun 10. doi: 10.1111/dom.13809. [Epub ahead of print]

PMID:
31183945
7.

Association Between Layer-Specific Longitudinal Strain and Risk Factors of Heart Failure and Dyspnea: A Population-Based Study.

Huttin O, Girerd N, Coiro S, Bozec E, Selton-Suty C, Lamiral Z, Frikha Z, Kobayashi M, Argulian E, Narula J, Fraser AG, Rossignol P, Zannad F.

J Am Soc Echocardiogr. 2019 Jul;32(7):854-865.e8. doi: 10.1016/j.echo.2019.03.011. Epub 2019 May 16.

PMID:
31104890
8.

Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure.

Ferreira JP, Verdonschot J, Collier T, Wang P, Pizard A, Bär C, Björkman J, Boccanelli A, Butler J, Clark A, Cleland JG, Delles C, Diez J, Girerd N, González A, Hazebroek M, Huby AC, Jukema W, Latini R, Leenders J, Levy D, Mebazaa A, Mischak H, Pinet F, Rossignol P, Sattar N, Sever P, Staessen JA, Thum T, Vodovar N, Zhang ZY, Heymans S, Zannad F.

Circ Heart Fail. 2019 May;12(5):e005897. doi: 10.1161/CIRCHEARTFAILURE.118.005897.

PMID:
31104495
9.

Estimated Long-Term Survival With Eplerenone.

Stienen S, Ferreira JP, Vincent J, Busselen M, Li B, McMurray JJV, Pitt B, Girerd N, Rossignol P, Zannad F.

J Am Coll Cardiol. 2019 May 14;73(18):2357-2359. doi: 10.1016/j.jacc.2019.02.043. No abstract available.

PMID:
31072582
10.

Plasma protein biomarkers and their association with mutually exclusive cardiovascular phenotypes: the FIBRO-TARGETS case-control analyses.

Ferreira JP, Pizard A, Machu JL, Bresso E, Rocca HB, Girerd N, Leroy C, González A, Diez J, Heymans S, Devignes MD, Rossignol P, Zannad F; FIBRO-TARGETS investigators.

Clin Res Cardiol. 2019 May 6. doi: 10.1007/s00392-019-01480-4. [Epub ahead of print]

PMID:
31062082
11.

Low fibrosis biomarker levels predict cardiac resynchronization therapy response.

Massoullié G, Sapin V, Ploux S, Rossignol P, Mulliez A, Jean F, Marie PY, Merlin C, Pereira B, Andronache M, Motreff P, Chabin X, Sellal JM, Citron B, Lusson JR, Vorilhon C, Clerfond G, Bordachar P, Zannad F, Eschalier R.

Sci Rep. 2019 Apr 15;9(1):6103. doi: 10.1038/s41598-019-42468-4.

12.

Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative.

Stienen S, Ferreira JP, Girerd N, Duarte K, Lamiral Z, McMurray JJV, Pitt B, Dickstein K, Zannad F, Rossignol P; High-Risk Myocardial Infarction Database Initiative.

Clin Res Cardiol. 2019 Apr 5. doi: 10.1007/s00392-019-01453-7. [Epub ahead of print]

PMID:
30953180
13.

Extracting Meaning of Tubular Injury Molecules: Implications for Cardiorenal Health.

Rossignol P, Ferreira JP.

Am J Nephrol. 2019;49(5):343-345. doi: 10.1159/000499533. Epub 2019 Apr 2. No abstract available.

14.

The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward.

Rossignol P, Frimat L, Zannad F.

Kidney Int. 2019 Apr;95(4):747-749. doi: 10.1016/j.kint.2018.12.006.

PMID:
30904064
15.

Heart failure drug treatment.

Rossignol P, Hernandez AF, Solomon SD, Zannad F.

Lancet. 2019 Mar 9;393(10175):1034-1044. doi: 10.1016/S0140-6736(18)31808-7. Review.

PMID:
30860029
16.

A new area for the management of hyperkalaemia with potassium binders: clinical use in nephrology.

Rossignol P.

Eur Heart J Suppl. 2019 Feb;21(Suppl A):A48-A54. doi: 10.1093/eurheartj/suy032. Epub 2019 Feb 26.

17.

Impact of renin-angiotensin system inhibitors continuation versus discontinuation on outcome after major surgery: protocol of a multicenter randomized, controlled trial (STOP-or-NOT trial).

Legrand M, Futier E, Leone M, Deniau B, Mebazaa A, Plaud B, Coriat P, Rossignol P, Vicaut E, Gayat E; STOP-OR-NOT study investigators.

Trials. 2019 Mar 5;20(1):160. doi: 10.1186/s13063-019-3247-1.

18.

Management of hyperkalemia in the acutely ill patient.

Dépret F, Peacock WF, Liu KD, Rafique Z, Rossignol P, Legrand M.

Ann Intensive Care. 2019 Feb 28;9(1):32. doi: 10.1186/s13613-019-0509-8. Review.

19.

Mid-term prognostic impact of residual pulmonary congestion assessed by radiographic scoring in patients admitted for worsening heart failure.

Kobayashi M, Watanabe M, Coiro S, Bercker M, Paku Y, Iwasaki Y, Chikamori T, Yamashina A, Duarte K, Ferreira JP, Rossignol P, Zannad F, Girerd N.

Int J Cardiol. 2019 Aug 15;289:91-98. doi: 10.1016/j.ijcard.2019.01.091. Epub 2019 Feb 8.

PMID:
30770263
20.

Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial.

Ferreira JP, Abreu P, McMurray JJV, van Veldhuisen DJ, Swedberg K, Pocock SJ, Vincent J, Lins K, Rossignol P, Pitt B, Zannad F.

Eur J Heart Fail. 2019 Mar;21(3):345-351. doi: 10.1002/ejhf.1400. Epub 2019 Feb 15.

PMID:
30768732
21.

Nondipping Pattern and Cardiovascular and Renal Damage in a Population-Based Study (The STANISLAS Cohort Study).

Lopez-Sublet M, Girerd N, Bozec E, Machu JL, Ferreira JP, Zannad F, Mourad JJ, Rossignol P.

Am J Hypertens. 2019 Jun 11;32(7):620-628. doi: 10.1093/ajh/hpz020.

PMID:
30753257
22.

Balancing Benefits and Risks of Spironolactone in HFpEF and Chronic Kidney Disease Patients: Mind the Gap of Biological Monitoring!

Rossignol P, Ferreira JP.

JACC Heart Fail. 2019 Jan;7(1):33-35. doi: 10.1016/j.jchf.2018.11.016. No abstract available.

PMID:
30606485
23.

The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology.

Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, Testani JM, Tang WHW, Orso F, Rossignol P, Metra M, Filippatos G, Seferovic PM, Ruschitzka F, Coats AJ.

Eur J Heart Fail. 2019 Feb;21(2):137-155. doi: 10.1002/ejhf.1369. Epub 2019 Jan 1. Review.

PMID:
30600580
24.

Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers or both in incident end-stage renal disease patients without cardiovascular disease: a propensity-matched longitudinal cohort study.

Ferreira JP, Couchoud C, Gregson J, Tiple A, Glowacki F, London G, Agarwal R, Rossignol P.

Nephrol Dial Transplant. 2019 Jul 1;34(7):1216-1222. doi: 10.1093/ndt/gfy378.

PMID:
30590716
25.

Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure.

Zannad F, Rossignol P.

Circulation. 2019 Jan 15;139(3):362-365. doi: 10.1161/CIRCULATIONAHA.118.038399. No abstract available.

PMID:
30586788
26.

Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.

Savarese G, Xu H, Trevisan M, Dahlström U, Rossignol P, Pitt B, Lund LH, Carrero JJ.

JACC Heart Fail. 2019 Jan;7(1):65-76. doi: 10.1016/j.jchf.2018.10.003. Epub 2018 Dec 12.

PMID:
30553905
27.

The unit of Estimated Plasma Volume in Patients with Heart Failure using the Strauss-derived Duarte formula is not liter but dL/g.

Kobayashi M, Huttin O, Rossignol P, Girerd N.

J Card Fail. 2019 Feb;25(2):140. doi: 10.1016/j.cardfail.2018.12.002. Epub 2018 Dec 13. No abstract available.

PMID:
30552968
28.

Author Correction: Lipid management in patients with chronic kidney disease.

Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, Massy ZA, Mallamaci F, Valdivielso JM, Malyszko J, Verhaar MC, Ekart R, Vanholder R, London G, Ortiz A, Zoccali C.

Nat Rev Nephrol. 2019 Feb;15(2):121. doi: 10.1038/s41581-018-0099-y.

PMID:
30538326
29.

Low N-terminal pro-brain natriuretic peptide levels are associated with non-alcoholic fatty liver disease in patients with type 2 diabetes.

Johansen ML, Schou M, Rasmussen J, Rossignol P, Holm MR, Chabanova E, Dela F, Faber J, Kistorp C.

Diabetes Metab. 2018 Nov 22. pii: S1262-3636(18)30218-0. doi: 10.1016/j.diabet.2018.11.003. [Epub ahead of print]

PMID:
30472196
30.

Echocardiographic diastolic function evolution in patients with an anterior Q-wave myocardial infarction: insights from the REVE-2 study.

Ferreira JP, Bauters C, Eschalier R, Lamiral Z, Fay R, Huttin O, Girerd N, Zannad F, Pinet F, Rossignol P.

ESC Heart Fail. 2019 Feb;6(1):70-79. doi: 10.1002/ehf2.12359. Epub 2018 Nov 20.

31.

Correction to: Prognostic value of estimated plasma volume in acute heart failure in three cohort studies.

Kobayashi M, Rossignol P, Ferreira JP, Aragão I, Paku Y, Iwasaki Y, Watanabe M, Fudim M, Duarte K, Zannad F, Girerd N.

Clin Res Cardiol. 2019 May;108(5):562. doi: 10.1007/s00392-018-1390-4.

PMID:
30402715
32.

EPURE Transplant (Eplerenone in Patients Undergoing Renal Transplant) study: study protocol for a randomized controlled trial.

Girerd S, Frimat L, Ducloux D, Le Meur Y, Mariat C, Moulin B, Mousson C, Rieu P, Dali-Youcef N, Merckle L, Lepage X, Rossignol P, Girerd N, Jaisser F.

Trials. 2018 Oct 30;19(1):595. doi: 10.1186/s13063-018-2956-1.

33.

Diagnostic and prognostic value of plasma volume status at emergency department admission in dyspneic patients: results from the PARADISE cohort.

Chouihed T, Rossignol P, Bassand A, Duarte K, Kobayashi M, Jaeger D, Sadoune S, Buessler A, Nace L, Giacomin G, Hutter T, Barbé F, Salignac S, Jay N, Zannad F, Girerd N.

Clin Res Cardiol. 2019 May;108(5):563-573. doi: 10.1007/s00392-018-1388-y. Epub 2018 Oct 28.

PMID:
30370469
34.

Lipid management in patients with chronic kidney disease.

Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, Massy ZA, Mallamaci F, Valdivielso JM, Malyszko J, Verhaar MC, Ekart R, Vanholder R, London G, Ortiz A, Zoccali C.

Nat Rev Nephrol. 2018 Dec;14(12):727-749. doi: 10.1038/s41581-018-0072-9. Review. Erratum in: Nat Rev Nephrol. 2019 Feb;15(2):121.

PMID:
30361677
35.

Cardiorenal Syndrome Revisited.

Zannad F, Rossignol P.

Circulation. 2018 Aug 28;138(9):929-944. doi: 10.1161/CIRCULATIONAHA.117.028814.

PMID:
30354446
36.

Stress myocardial perfusion gated-SPECT imaging in advanced chronic kidney disease.

Marie PY, Rossignol P.

J Nucl Cardiol. 2018 Oct 22. doi: 10.1007/s12350-018-1412-7. [Epub ahead of print] No abstract available.

PMID:
30350266
37.

Hyperkalemia in the emergency department: Consider the use of nebulized salbutamol.

Montassier E, Legrand M, Rossignol P, Potel G.

Am J Emerg Med. 2019 May;37(5):1004. doi: 10.1016/j.ajem.2018.10.024. Epub 2018 Oct 16. No abstract available.

PMID:
30348470
38.

Prognostic value of estimated plasma volume in acute heart failure in three cohort studies.

Kobayashi M, Rossignol P, Ferreira JP, Aragão I, Paku Y, Iwasaki Y, Watanabe M, Fudim M, Duarte K, Zannad F, Girerd N.

Clin Res Cardiol. 2019 May;108(5):549-561. doi: 10.1007/s00392-018-1385-1. Epub 2018 Oct 19. Erratum in: Clin Res Cardiol. 2018 Nov 6;:.

PMID:
30341579
39.

Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology.

Maack C, Lehrke M, Backs J, Heinzel FR, Hulot JS, Marx N, Paulus WJ, Rossignol P, Taegtmeyer H, Bauersachs J, Bayes-Genis A, Brutsaert D, Bugger H, Clarke K, Cosentino F, De Keulenaer G, Dei Cas A, González A, Huelsmann M, Iaccarino G, Lunde IG, Lyon AR, Pollesello P, Rena G, Riksen NP, Rosano G, Staels B, van Laake LW, Wanner C, Farmakis D, Filippatos G, Ruschitzka F, Seferovic P, de Boer RA, Heymans S.

Eur Heart J. 2018 Dec 21;39(48):4243-4254. doi: 10.1093/eurheartj/ehy596. No abstract available.

40.

Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial.

Ferreira JP, Barros A, Pitt B, Montalescot G, de Sa EL, Hamm CW, Flather M, Verheugt F, Shi H, Leite-Moreira A, Vincent J, Rossignol P, Zannad F.

Clin Res Cardiol. 2018 Dec;107(12):1192-1195. doi: 10.1007/s00392-018-1373-5. Epub 2018 Sep 27. No abstract available.

PMID:
30264283
41.

Editor's Choice- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction.

Rossello X, Ferreira JP, McMurray JJ, Aguilar D, Pfeffer MA, Pitt B, Dickstein K, Girerd N, Rossignol P, Zannad F; High-Risk Myocardial Infarction Database Initiative.

Eur Heart J Acute Cardiovasc Care. 2019 Apr;8(3):231-241. doi: 10.1177/2048872618803701. Epub 2018 Sep 27.

PMID:
30259764
42.

Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations.

Covic A, Genovesi S, Rossignol P, Kalra PA, Ortiz A, Banach M, Burlacu A.

BMC Med. 2018 Sep 19;16(1):158. doi: 10.1186/s12916-018-1145-0.

43.

Heart rate, pulse pressure and mortality in patients with myocardial infarction complicated by heart failure.

Dobre D, Kjekshus J, Rossignol P, Girerd N, Benetos A, Dickstein K, Zannad F.

Int J Cardiol. 2018 Nov 15;271:181-185. doi: 10.1016/j.ijcard.2018.05.017.

PMID:
30223350
44.

Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.

Agarwal R, Rossignol P, Garza D, Mayo MR, Warren S, Arthur S, Romero A, White WB, Williams B.

Am J Nephrol. 2018;48(3):172-180. doi: 10.1159/000492622. Epub 2018 Sep 3.

45.

Health-related determinants of undiagnosed arterial hypertension: a population-based study.

Chau K, Girerd N, Zannad F, Rossignol P, Boivin JM.

Fam Pract. 2019 May 23;36(3):276-283. doi: 10.1093/fampra/cmy075.

PMID:
30165649
46.

Relationship between left ventricular ejection fraction and mortality after myocardial infarction complicated by heart failure or left ventricular dysfunction.

Hall TS, von Lueder TG, Zannad F, Rossignol P, Duarte K, Chouihed T, Dickstein K, Atar D, Agewall S, Girerd N; High-Risk Myocardial Infarction Database Initiative investigators.

Int J Cardiol. 2018 Dec 1;272:260-266. doi: 10.1016/j.ijcard.2018.07.137. Epub 2018 Jul 29.

PMID:
30144995
47.

Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure.

Ferreira JP, Rossignol P, Pizard A, Machu JL, Collier T, Girerd N, Huby AC, Gonzalez A, Diez J, López B, Sattar N, Cleland JG, Sever PS, Zannad F.

Heart. 2018 Aug 18. pii: heartjnl-2018-313182. doi: 10.1136/heartjnl-2018-313182. [Epub ahead of print]

48.

Relation of Serum Potassium to Cardiovascular Events in Patients With Heart Failure and Preserved Ejection Fraction: "Mind the Gap".

Pitt B, Rossignol P.

Am J Hypertens. 2018 Sep 11;31(10):1087-1089. doi: 10.1093/ajh/hpy107. No abstract available.

PMID:
30060111
49.

Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns.

Ferreira JP, Duarte K, McMurray JJV, Pitt B, van Veldhuisen DJ, Vincent J, Ahmad T, Tromp J, Rossignol P, Zannad F.

Circ Heart Fail. 2018 Jul;11(7):e004926. doi: 10.1161/CIRCHEARTFAILURE.118.004926.

PMID:
29997240
50.

Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction.

Levy B, Clere-Jehl R, Legras A, Morichau-Beauchant T, Leone M, Frederique G, Quenot JP, Kimmoun A, Cariou A, Lassus J, Harjola VP, Meziani F, Louis G, Rossignol P, Duarte K, Girerd N, Mebazaa A, Vignon P; Collaborators.

J Am Coll Cardiol. 2018 Jul 10;72(2):173-182. doi: 10.1016/j.jacc.2018.04.051.

Supplemental Content

Loading ...
Support Center